Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS

被引:30
作者
Hegstad, S. [1 ]
Khiabani, H. Z. [1 ]
Oiestad, E. L. [1 ]
Berg, T. [1 ]
Christophersen, A. S. [1 ]
机构
[1] Norwegian Inst Publ Hlth, Div Forens Toxicol & Drug Abuse, NO-0403 Oslo, Norway
关键词
D O I
10.1093/jat/31.4.214
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A liquid chromatography-tandem mass spectrometry (LC-MS-MS) method was developed and validated for the determination of buprenorphine-glucuronide (BUP-G) and norbuprenorphine-glucuronide (NBUP-G) in human urine. The method included a dilution step followed by filtration through a Mini-Uniprep Filter and direct injection onto the LC column. The analytes were quantified in multiple reactions monitoring mode using one transition ion. Norbuprenorpine-d3 (NBUP-d3) was used as the internal standard. The concentration ranges were 6-161 ng/mL for BUP-G and 12-295 ng/mL for NBUP-G. Recoveries determined after filtration for the analytes were 75%. The between-day precision of the method was in the range of 4.8-11%. The limits of quantification were found to be 4.6 ng/mL for BUP-G and 11.8 ng/mL for NBUP-G. Approximately 1000 samples from law enforcement, prison inmates, probation services, and hospitals were analyzed by the presented method. The ratios of drug glucuronides versus creatinine were calculated for a selection of samples (n = 151), where there was information on treatment with buprenorphine between 16 and 20 mg/day. The majority (86%) of the samples had a ratio of BUP-G/creatinine below 570 μ g/g, and 76% of the samples had NBUP-G/creatinine lower than 1060 μ g/g. The LC-MS-MS method proved to be robust and specific for the determination of BUP-G and NBUP-G in urine.
引用
收藏
页码:214 / 219
页数:6
相关论文
共 28 条
[1]   Ion suppression in mass spectrometry [J].
Annesley, TM .
CLINICAL CHEMISTRY, 2003, 49 (07) :1041-1044
[2]   Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients [J].
Bickel, WK ;
Amass, L ;
Crean, JP ;
Badger, GJ .
PSYCHOPHARMACOLOGY, 1999, 146 (02) :111-118
[3]   Sensitive determination of buprenorphine and its N-dealkylated metabolite norbuprenorphine in human plasma by liquid chromatography coupled to tandem mass spectrometry [J].
Ceccato, A ;
Klinkenberg, R ;
Hubert, P ;
Streel, B .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 32 (4-5) :619-631
[4]   Novel metabolites of buprenorphine detected in human liver microsomes and human urine [J].
Chang, Y ;
Moody, DE ;
McCance-Katz, EF .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (03) :440-448
[5]  
CONE EJ, 1984, DRUG METAB DISPOS, V12, P577
[6]   STABILITY OF THE "6,14-ENDO-ETHANOTETRAHYDROORIPAVINE ANALGESICS - ACID-CATALYZED REARRANGEMENT OF BUPRENORPHINE [J].
CONE, EJ ;
GORODETZKY, CW ;
DARWIN, WD ;
BUCHWALD, WF .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (02) :243-246
[7]   AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT [J].
COWAN, A ;
LEWIS, JW ;
MACFARLANE, IR .
BRITISH JOURNAL OF PHARMACOLOGY, 1977, 60 (04) :537-545
[8]   Hydrolysis of conjugated metabolites of buprenorphine -: II.: The quantitative enzymatic hydrolysis of norbuprenorphine-3-β-D-glucuronide in human urine [J].
ElSohly, MA ;
Gul, W ;
Feng, SX ;
Murphy, TP .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2005, 29 (06) :570-573
[9]   Hydrolysis of conjugated metabolites of buprenorphine.: I.: The quantitative enzymatic hydrolysis of buprenorphine-3-β-D-glucuronide in human urine [J].
Feng, SX ;
ElSohly, MA ;
Duckworth, DT .
JOURNAL OF ANALYTICAL TOXICOLOGY, 2001, 25 (07) :589-593
[10]   Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone [J].
Fudala, PJ ;
Bridge, TP ;
Herbert, S ;
Williford, WO ;
Chiang, CN ;
Jones, K ;
Collins, J ;
Raisch, D ;
Casadonte, P ;
Goldsmith, RJ ;
Ling, W ;
Malkerneker, U ;
McNicholas, L ;
Renner, J ;
Stine, S ;
Tusel, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :949-958